Deanol Aceglumate PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
3342-61-8
Molecular formula
C11H22N2O6
Molecular weight
278.3 g/mol
Drug class
CNS stimulant and cholinergic precursor saltdeanol–N-acetyl-L-glutamate
Mechanism of action
A salt of deanol (2-dimethylaminoethanol) and N-acetyl-L-glutamate. Deanol is a choline-related precursor that has been proposed to influence acetylcholine availability and central cholinergic signalling; the pharmacological contribution of the aceglumate countercomponent and clinical mechanism are not well established.
Indications / reported uses
Marketed in some countries for cognitive symptoms or neurological complaints, but clinical efficacy evidence and authorised indications are limited and jurisdiction-specific. It should not be presented as an established treatment for dementia or other neurodegenerative disease.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Deanol Aceglumate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Deanol Aceglumate Permitted Daily Exposure (PDE) report (the Deanol Aceglumate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Deanol Aceglumate Occupational Exposure Limit (OEL) report (the Deanol Aceglumate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.